Brain damage from anticancer treatments in adults

Current Opinion in Oncology

Volumn 21, Issue 6, 2009, Pages 559-565

  Ricard, Damien ^a,b,c   Taillia, Hervé ^a   Renard, Jean Luc ^a  

^a University of Paris Descartes   (France)

^b INSERM   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Brain radionecrosis; Chemobrain; Cognitive side effects; Leukoencephalopathy; Neurotoxicity

Indexed keywords

ANTINEOPLASTIC AGENT; ANTIOXIDANT; BEVACIZUMAB; CARMUSTINE; CHOLINESTERASE INHIBITOR; CISPLATIN; CORTICOSTEROID DERIVATIVE; CYCLOPHOSPHAMIDE; DOPAMINE RECEPTOR STIMULATING AGENT; DOXORUBICIN; EPIRUBICIN; ERYTHROPOIETIN; FLUOROURACIL; GEFITINIB; GROWTH FACTOR; LOMUSTINE; MEMANTINE; METHOTREXATE; METHYLPHENIDATE; MODAFINIL; MONOAMINE OXIDASE INHIBITOR; NITROSOUREA; PACLITAXEL; PROCARBAZINE; RECOMBINANT ERYTHROPOIETIN; RILUZOLE; TAMOXIFEN; TEMOZOLOMIDE; UNINDEXED DRUG; VINCRISTINE;

ADULT; BRAIN FUNCTION; BRAIN METASTASIS; BRAIN NECROSIS; BRAIN RADIATION; BRAIN SURGERY; BRAIN TOXICITY; BRAIN TUMOR; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PREVENTION; CANCER RISK; CANCER SURVIVOR; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE DEFECT; COLORECTAL CANCER; DRUG EFFICACY; DRUG MEGADOSE; GLIOBLASTOMA; GLIOMA; HUMAN; LEUKOENCEPHALOPATHY; LUNG SMALL CELL CANCER; LYMPHOMA; MULTIPLE CYCLE TREATMENT; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PRIORITY JOURNAL; QUALITY OF LIFE; RADIATION DOSE; RADIATION NECROSIS; RADIATION SAFETY; RADIOSURGERY; REVIEW; TREATMENT RESPONSE; TUMOR RECURRENCE; WHOLE BODY RADIATION; BRAIN; BRAIN INJURY; DRUG EFFECT; DRUG THERAPY; MULTIMODALITY CANCER THERAPY; NEOPLASM; PATHOLOGY; RADIATION EXPOSURE; SKULL IRRADIATION;

ADULT; BRAIN; BRAIN INJURIES; COMBINED MODALITY THERAPY; CRANIAL IRRADIATION; DRUG THERAPY; HUMANS; LEUKOENCEPHALOPATHIES; NEOPLASMS; RADIOSURGERY;

EID: 74049155883     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e328330c669     Document Type: Review

References (32)

1. Dietrich J, Monje M, Wefel J, Meyers C. Clinical patterns and biological correlates of cognitive dysfunction associated with cancer therapy. Oncologist 2008; 13:1285-1295.
2. Yoshii Y. Pathological review of late cerebral radionecrosis. Brain Tumor Pathol 2008; 25:51-58.
3. Nomiya T, Nemoto K, Kumabe T, et al. Prospective single-arm study of 72 Gy hyperfractionated radiation therapy and combination chemotherapy for anaplastic astrocytomas. BMC Cancer 2008; 8:11. doi:10.1186/1471-2407-811. (Pubitemid 351325336)
4. Smith KA, Ashby LS, Gonzalez F, et al. Prospective trial of gross-total resection with Gliadel wafers followed by early postoperative Gamma Knife radiosurgery and conformal fractionated radiotherapy as the initial treatment for patients with radiographically suspected, newly diagnosed glioblastoma multiforme. J Neurosurg 2008; 109:106-117.
5. Schwer AL, Kavanagh BD, McCammon R, et al. Radiographic and histopathologic observations after combined EGFR inhibition and hypofractlonated stereotactic radiosurgery in patients with recurrent malignant gliomas. Int J Radiat Oncol Biol Phys 2009; 73:1352-1357.
6. Brandsma D, Stalpers L, Taal W, et al. Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol 2008; 9:453-461. (Pubitemid 351597795)
7. Taal W, Brandsma D, de Bruin HG, et al. Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomlde. Cancer 2008; 113:405-410.
8. Brandes AA, Franceschi E, Tosoni A, et al. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol 2008; 26:2192-2197.
9. Chamberlain MC, Glantz MJ, Chalmers L, et al. Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma. J Neurooncol 2007; 82:81-83. (Pubitemid 46252277)
10. Torcuator R, Zuniga R, Mohan YS, et al. Initial experience with bevaclzumab treatment for biopsy confirmed cerebral radiation necrosis. J Neurooncol 2009; 94:63-68.
11. Gonzalez J, Kumar AJ, Conrad CA, Levin VA. Effect of bevacizumab on radiation necrosis of the brain. Int J Radiat Oncol Biol Phys 2007; 67:323-326. (Pubitemid 46108339)
12. Correa DD, Shi W, Thaler HT, et al. Longitudinal cognitive follow-up in low grade gliomas. J Neurooncol 2008; 86:321-327.
13. Sierra del Rio M, Rousseau A, Soussain C, et al. Primary CNS lymphoma in immunocompetent patients. Oncologist 2009; 14:526-539.
14. Correa DD, Rocco-Donovan M, DeAngelis LM, et al. Prospective cognitive follow-up in primary CNS lymphoma patients treated with chemotherapy and reduced-dose radiotherapy. J Neurooncol 2009; 91:315-321.
15. Illerhaus G, Marks R, Müller F, et al. High-dose methotrexate combined with procarbazine and CCNU for primary CNS lymphoma in the elderly: results of a prospective pilot and phase II study. Ann Oncol 2009; 20:319-325.
16. Li J, Bentzen SM, Li J, et al. Relationship between neurocognitlve function and quality of life after whole-brain radiotherapy in patients with brain metastasis. Int J Radiat Oncol Biol Phys 2008; 71:64-70.
17. Nagesh V, Tsien Cl, Chenevert TL, et al. Radiation-induced changes in normal-appearing white matter in patients with cerebral tumors: a diffusion tensor imaging study. Int J Radiat Oncol Biol Phys 2008; 70:1002-1010. (Pubitemid 351296105)
18. Pöttgen C, Eberhardt W, Grannas A, et al. Prophylactic cranial irradiation in operable stage IIIA non small-cell lung cancer treated with neoadjuvant chemoradiotherapy: results from a German multlcenter randomized trial. J Clin Oncol 2007; 25:4987-4992. (Pubitemid 350220432)
19. Grosshans DR, Meyers CA, Allen PK, et al. Neurocognitlve function in patients with small-cell lung cancer. Effects of prophylactic cranial irradiation. Cancer 2008; 112:589-595.
20. Welzel G, Fleckenstein K, Schaefer J, et al. Memory function before and after whole brain radiotherapy in patients with and without brain metastases. Int J Radiat Oncol Biol Phys 2008; 72:1311-1318.
21. Slotman BJ, Mauer ME, Bottomley A, et al. Prophylactic cranial irradiation in extensive disease small-ceel lung cancer: short-term health-related quality of life and patient reported symptoms - results of international phase III randomized controlled trial by the EORTC Radiation Oncology and Lung Cancer Groups. J Clin Oncol 2009; 27:78-84.
22. Vardy J. Cognitive function in survivors of cancer. Education Book ASCO 2009: 570-574.
23. Vardy J, Wefel J, Ahlhes T, et al. Cancer and cancer-therapy related cognitive dysfunction: an international perspective from the Venice cognitive workshop. Ann Oncol 2008; 19:623-626.
24. Mehlsen M, Pedersen A, Jensen A, Zacharlae R. No indications of cognitive side-effects in a prospective study of breast cancer patients receiving adjuvant chemotherapy. Psychooncology 2009; 18:248-257.
25. Talllibert S, Volllery D, Bernard-Marty C. Chemobrain : is systemic chemotherapy neurotoxic? Curr Opin Oncol 2007; 19:623-627.
26. Steffen-Smith E, Wolters P, Albert P, et al. Detection and characterization of neurotoxicity in cancer patients using proton MR spectroscopy. Childs Nerv Syst 2008; 24:807-813.
27. Hermelink K, Henschel V, Untch M, et al. Short-term effects of treatmentinduced hormonal changes on cognition function in breast cancer patients. Cancer 2008; 113:2431-2439.
28. Mar Fan H, Park A, Xu W, et al. The influence of erythropoietin on cognitive function in women following chemotherapy for breast cancer. Psychooncology 2009; 18:156-161.
29. Jackson G. Chemobrain - a psychotropic drug phenomenon? Med Hypoth 2008; 70:572-577.
30. Seigers R, Schagen S, Beerling W, et al. Long-lasting suppression of hippocampal cell proliferation and impaired cognitive performance by methotrexate in the rat. Behav Brain Res 2008; 186:168-175. (Pubitemid 350122748)
31. Seruga B, Zhang H, Bernstein L, et al. Cytokines and their relationship to the symptoms and outcome of cancer. Nat Rev Cancer 2008; 8:887-899.
32. Ahles TA, Saykin AJ, McDonald BC, Furstenberg CT, et al. Cognitive function in breast cancer patients prior to adjuvant treatment. Breast Cancer Res Treat 2008; 110:143-152. (Pubitemid 351793851)